Mannatech results
This article was originally published in The Tan Sheet
Executive Summary
Firm's net sales increase 7.6% to $58.4 mil., with earnings up 118.8% to $3.1 mil. in the first quarter (ended March 31). Mannatech attributes the results to "building momentum" from new and existing associates and members. The firm's sales associates brought 141,000 new customers in the 12 months ended March 31, according to CEO Samuel Caster. Mannatech plans to launch products in South Korea in the third quarter and roll out Ambrotose AO in the United Kingdom, Japan, Australia and New Zealand later this year...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.